• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

After seeing its GSK-backed trial ditched, LAG-3-focused Immutep secures cash, plots new...

cafead

Administrator
Staff member
  • cafead   Jun 21, 2021 at 11:22: AM
via Australian biotech Immutep has secured $60 million Australian dollars through a “two-tranche institutional placement” as it eyes a deeper push into the clinic and looks to raise a further AU$5 million via a share purchase plan.

article source
 

<